AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)
Executive Summary
The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.
You may also be interested in...
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Latest WHO Essential Medicines List: New Drugs And A New Way Of Tackling Antibiotic Resistance
New drugs for leukemia, hepatitis C, HIV and tuberculosis have made it onto the 20th edition of the World Health Organization’s Essential Medicines List, which also features a new categorization system for antibiotics in a fresh effort to curb the rise of antibacterial resistance.
Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug
If approved, Zolyd will be the first intravenous epoxide antibiotic approved in the US, with greater potency than the oral version used first-line. Ex-US, the I.V. formulation has demonstrated a stable resistance profile.